Drug Profile
Bevacizumab biobetter - Prestige BioPharma
Alternative Names: Avastin biobetter - Prestige BioPharma; PBP 1503Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Biobetters; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Solid tumours (Second-line therapy or greater, Treatment-resistant) in Singapore (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Solid-tumours(Second-line therapy or greater, Treatment-resistant) in Singapore (Parenteral)
- 18 Jan 2017 Preclinical trials in Solid tumours (Second-line therapy or greater, Treatment-resistant) in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)